GSK has entered an agreement to acquire Canadian biotechnology company 35Pharma for $950 million in order to strengthen its pipeline of therapies for pulmonary hypertension and related cardiopulmonary ...

Acquisition includes HS235, a potentially best-in-class activin signalling inhibitor in clinical development for treatment of cardiopulmonary diseases HS235 offers potential to treat pulmonary ...

An increase in the number of percutaneous coronary interventions does not appear to have resulted in reduced mortality rates, ...

BACKGROUND: BCR-ABL tyrosine kinase inhibitors (TKIs) have been increasingly linked to pulmonary arterial hypertension (PAH) since 2009, although supporting evidence is limited. Our objective was to ...

A stepwise approach to perioperative cardiac assessment assists clinicians in determining when surgery should proceed or when a pause for further evaluation is warranted. Cardiovascular screening and ...

Integrating the Geriatric 5Ms (mind, mobility, medications, what matters most, and multicomplexity) into clinical practice allows for personalized cardiovascular care that balances intensive risk ...

ABSTRACT: Background: Self-medication with antihypertensive drugs is a common practice in sub-Saharan Africa that may contribute to poor blood pressure control and cardiovascular complications.

Nearly half of U.S. adults have high blood pressure, the top preventable risk factor for heart disease, stroke, heart attack, heart failure, kidney disease, and even dementia. For the first time since ...